New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - lamivudine 150mg; zidovudine 300mg - film coated tablet - active: lamivudine 150mg zidovudine 300mg excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose opadry white propylene glycol purified water sodium starch glycolate - indicated for the treatment of hiv infected adults and adolescents over the age of 12 years, with progressive immunodeficiency (cd4+ count = < 500 cells/mm³).

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - solution (oral) - lamivudine 10 mg/ml - lamivudine - lamivudine - epivir is indicated as part of antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected adults and children.

Malta - English - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - zidovudine, lamivudine - film-coated tablet - zidovudine 300 milligram(s) ; lamivudine 150 milligram(s) - antivirals for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - lamivudine; abacavir - film-coated tablet - 600 mg/300 milligram(s)

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - abacavir; lamivudine - film-coated tablet - 600 mg/300 milligram(s) - antivirals for treatment of hiv infections, combinations; lamivudine and abacavir

European Union - English - EMA (European Medicines Agency)

viiv healthcare bv - lamivudine, zidovudine - hiv infections - antivirals for systemic use - combivir is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection.,

European Union - English - EMA (European Medicines Agency)

viiv healthcare bv - lamivudine - hiv infections - antivirals for systemic use - epivir is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (hiv)-infected adults and children.,

European Union - English - EMA (European Medicines Agency)

viiv healthcare bv - abacavir, lamivudine - hiv infections - antivirals for treatment of hiv infections, combinations, antivirals for systemic use - kivexa is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults, adolescents and children weighing at least 25 kg.before initiating treatment with abacavir, screening for carriage of the hla-b*5701 allele should be performed in any hiv-infected patient, irrespective of racial origin. abacavir should not be used in patients known to carry the hla-b*5701 allele.

European Union - English - EMA (European Medicines Agency)

teva b.v. - lamivudine - hepatitis b, chronic - antivirals for systemic use - lamivudine teva is indicated for the treatment of chronic hepatitis b in adults with:compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active liver inflammation and / or fibrosis. initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see in section 5.1).

European Union - English - EMA (European Medicines Agency)

teva b.v.  - lamivudine - hiv infections - antivirals for systemic use - lamivudine teva pharma b.v. is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (hiv)-infected adults and children.